Abstract:Objective To observe the efficacy and safety of recombinant human interleukin-11 (mIL-11) in the treatment of thrombocytopenia induced by chemoradiotherapy in patients with solid tumor. Methods Solid tumor patients whose PLT count was lower than 50×109/L from December 2010 to December 2012 in PLA general hospital of Chengdu Commond were studied. They were divided into two groups randomly. The observed group was given subcutaneous injection of recombinant human interleukin-11(Ⅰ) at the dose of 25 g·kg-1·d-1, until the PLT rising subsolute value was more than 50×109/L. The control group was given usual treatment. The vital signs, hepatorenal function, coagulation function and cardiopulmonary function of the patients were recorded during the whole process of treatment. Results The patients after chemotherapy had the platelet lowest average of (27.4±7.6)×109/L, and the average of the control group was (28.1±7.9)×109/L. The difference was not statistically significant (t=1.083, P>0.05), but treatment after the observation of elevated had the platelet highest average of (116.3±22.8)×109/L, which was significantly higher than that of (76.2±21.3)×109/L; the difference was significant (t=21.092, P<0.05). Platelets of patients in the observation group were <50×109/L for several days with an average of (4.3±1.7) d, while platelets rose from the lowest value of the average absolute value greater than 50 000 hours (6.8±2.4) d, shorter than the control group. By comparing the two groups, the differences were significant (t=11.347, P<0.05; t=15.196, P<0.05). Two groups of patients can tolerate adverse reactions. Ⅲ, Ⅳ degree of adverse reaction was not observed. Conclusion This study shows that rhIL-11 is well tolerated and has thrombopoietic activity in the treatment of thrombocytopenia.

Key words:Interleukin-11,Thrombocytopenia,Neoplasms